Danaher Co. (NYSE:DHR) Holdings Trimmed by Swedbank AB

Swedbank AB cut its holdings in Danaher Co. (NYSE:DHR) by 6.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,392,061 shares of the conglomerate’s stock after selling 173,852 shares during the quarter. Danaher comprises about 0.8% of Swedbank AB’s investment portfolio, making the stock its 23rd biggest holding. Swedbank AB owned 0.32% of Danaher worth $665,041,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of DHR. Oak Thistle LLC acquired a new stake in shares of Danaher during the second quarter worth $363,000. Norden Group LLC purchased a new stake in Danaher during the first quarter valued at about $4,151,000. Duality Advisers LP acquired a new position in shares of Danaher in the first quarter worth about $5,573,000. Investment Research & Advisory Group Inc. purchased a new position in shares of Danaher in the first quarter worth approximately $1,186,000. Finally, Diversified Trust Co raised its holdings in shares of Danaher by 75.4% during the second quarter. Diversified Trust Co now owns 4,360 shares of the conglomerate’s stock valued at $1,090,000 after acquiring an additional 1,874 shares during the period. 79.05% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Danaher news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the sale, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other Danaher news, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total value of $2,641,536.00. Following the sale, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $5,566,486.80. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the sale, the senior vice president now owns 4,212 shares in the company, valued at $1,130,374.44. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 39,659 shares of company stock valued at $11,042,433. 11.10% of the stock is owned by company insiders.

Danaher Trading Up 0.8 %

Shares of DHR traded up $2.08 during trading hours on Tuesday, hitting $273.64. 752,058 shares of the stock traded hands, compared to its average volume of 2,712,970. Danaher Co. has a 1-year low of $182.09 and a 1-year high of $281.70. The business has a fifty day moving average of $270.36 and a 200-day moving average of $259.43. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $202.68 billion, a PE ratio of 46.03, a price-to-earnings-growth ratio of 4.49 and a beta of 0.83.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. The firm had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business’s quarterly revenue was down 2.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.05 EPS. Analysts expect that Danaher Co. will post 7.59 EPS for the current year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be issued a $0.27 dividend. The ex-dividend date of this dividend is Friday, September 27th. This represents a $1.08 annualized dividend and a yield of 0.39%. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Analyst Ratings Changes

Several equities analysts have weighed in on DHR shares. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th. Wells Fargo & Company assumed coverage on Danaher in a research report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price target on the stock. Leerink Partners raised their price objective on Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. Stephens assumed coverage on Danaher in a report on Tuesday, October 1st. They issued an “overweight” rating and a $315.00 target price on the stock. Finally, Evercore ISI raised their price target on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Seven investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $282.12.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.